Division of Johnson & Johnson
Latest From Ethicon Inc.
Johnson & Johnson’s leadership remains optimistic about the future of its medical device divisions despite reporting a 2.6% revenue decline in the first six months of 2019 compared to the same period of 2018.
After heading up Lilly Bio-Medicines for two-and-a-half years, Shaw will take over Gilead’s gene therapy subsidiary. At Lilly, she oversaw the approvals of Olumiant and Emgality and helped grow Taltz.
Pacts In Medtech: Cook Will Sell Ambu’s Duodenoscopes; QXMedical Gets UMinnesota’s Bioresorbable Embolic
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in May and June 2019.
The global market for endoscopic and pelvic surgery procedures is expected to reach $17.7bn in 2023, a CAGR of 6.4%, driven by patients' demand for less invasive surgeries and physicians' preference for minimally invasive surgeries versus open surgeries. By 2023, the number of general and pelvic endoscopic procedures performed globally will reach about 29.7 million, representing a CAGR of 3.6%.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
Johnson & Johnson
- Acclarent Inc.
- Advanced Sterilization Products
- CardioVations Inc.
- Guangzhou Bioseal Biotechnology Co. Ltd.
- Gynecare Inc.
- Heartport Inc.
- Johnson & Johnson Medical Inc.
- Medtrex Inc.
- Mentor Corp.
- Omrix Biopharmaceuticals Inc.
- Torax Medical Inc.
- Vascular Control Systems Inc.
- Ethicon Inc.
- Senior Management
- Contact Info
Phone: (908) 218-0707
Rte. 22 West
Somerville, NJ 08876
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.